Pomotrelvir

Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 of 24 nM for wild-type SARS-CoV-2 Mpro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants[1][2].

Product Specifications

CAS Number

[2713437-86-4]

Product Name Alternative

PBI-0451

UNSPSC

12352005

Target

SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/pomotrelvir.html

Purity

96.73

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=C2C(C=C(N2)C(N[C@H](C(N[C@H](C#N)C[C@H]3C(NCCC3)=O)=O)CC4CC4)=O)=CC=C1

Molecular Formula

C23H26ClN5O3

Molecular Weight

455.94

References & Citations

[1]Tong X, et al. Evaluation of in vitro antiviral activity of SARS-CoV-2 Mpro inhibitor pomotrelvir and cross-resistance to nirmatrelvir resistance substitutions. Antimicrob Agents Chemother. 2023 Nov 15;67 (11) :e0084023.|[2]Schillings J, et al. Pomotrelvir and Nirmatrelvir Binding and Reactivity with SARS-CoV-2 Main Protease: Implications for Resistance Mechanisms from Computations. Angew Chem Int Ed Engl. 2024 Oct 1;63 (40) :e202409527.